Is AGL a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Margin-over-growth reset, with revenue (ttm) at ~$5.8B. The bear case rests on agilon carries meaningful medical-cost-trend risk: because it is paid a fixed amount per member, an unexpected rise in senior utilization or unit costs can swing it back to losses, which is what drove heavy prior-year losses. Analysts covering it are spread from $22.00 to $141.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. agilon carries meaningful medical-cost-trend risk: because it is paid a fixed amount per member, an unexpected rise in senior utilization or unit costs can swing it back to losses, which is what drove heavy prior-year losses. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $22.00, -77.2% from the $96.30 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Margin-over-growth reset. agilon has shifted from chasing membership to prioritizing profitable contracts, exiting weaker payer relationships and markets. The most optimistic analyst target on AGL is $141.00, +46.4% from the $96.30 price. That figure is only reachable if this thesis works close to its best case.

agilon carries meaningful medical-cost-trend risk: because it is paid a fixed amount per member, an unexpected rise in senior utilization or unit costs can swing it back to losses, which is what drove heavy prior-year losses. It is exposed to Medicare Advantage rate decisions, risk-adjustment methodology changes, and V28 model phase-in that pressure per-member revenue across the sector. The turnaround is early and depends on membership stabilizing after deliberate cuts, so profitability is not yet proven across a full year. As a small-cap with a modest share count, the stock can be volatile, and any single large market or payer contract going wrong is material. Historically it has been unprofitable on a GAAP full-year basis. The most pessimistic published target is $22.00, -77.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

agilon health provides a platform, capital, and technology that let community primary-care physician groups take on full financial risk for their senior patients, mostly Medicare A

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Margin-over-growth reset) stalling in the reported numbers rather than in the narrative, the risk above (agilon carries meaningful medical-cost-trend risk: because it is paid a fixed amount per member, an unexpected rise in senior utilization or unit costs can swing it back to losses, which is what drove heavy prior-year losses) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

agilon partners with community primary-care physician groups and gives them the platform, capital, and data to manage their senior patients under value-based, capitated Medicare contracts. Instead of billing per visit, agilon and its doctors are paid a fixed amount per member and keep savings when they keep patients healthier.

Historically no. agilon posted large GAAP losses in prior years, including a roughly $391 million net loss for full-year 2025. It reported positive net income of about $49 million in Q1 2026 and guided to positive full-year adjusted EBITDA, but sustained annual profitability is not yet proven.

By design. Management deliberately exited unprofitable payer contracts and markets to prioritize margin over growth, which cut Medicare Advantage membership by double digits. The goal is a smaller, higher-quality book with better medical margin per member rather than maximizing top-line revenue.